BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 25080849)

  • 1. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
    Seda V; Mraz M
    Eur J Haematol; 2015 Mar; 94(3):193-205. PubMed ID: 25080849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
    Smith CIE; Burger JA
    Front Immunol; 2021; 12():689472. PubMed ID: 34177947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Lymphocytic Leukemia: Disease Biology.
    Koehrer S; Burger JA
    Acta Haematol; 2024; 147(1):8-21. PubMed ID: 37717577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.
    Chen Z; Shojaee S; Buchner M; Geng H; Lee JW; Klemm L; Titz B; Graeber TG; Park E; Tan YX; Satterthwaite A; Paietta E; Hunger SP; Willman CL; Melnick A; Loh ML; Jung JU; Coligan JE; Bolland S; Mak TW; Limnander A; Jumaa H; Reth M; Weiss A; Lowell CA; Müschen M
    Nature; 2015 May; 521(7552):357-61. PubMed ID: 25799995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.
    Choi MY; Kipps TJ
    Cancer J; 2012; 18(5):404-10. PubMed ID: 23006944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
    Quiroga MP; Balakrishnan K; Kurtova AV; Sivina M; Keating MJ; Wierda WG; Gandhi V; Burger JA
    Blood; 2009 Jul; 114(5):1029-37. PubMed ID: 19491390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.
    Choi J; Phelan JD; Wright GW; Häupl B; Huang DW; Shaffer AL; Young RM; Wang Z; Zhao H; Yu X; Oellerich T; Staudt LM
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6092-6102. PubMed ID: 32127472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
    Valla K; Flowers CR; Koff JL
    Expert Opin Investig Drugs; 2018 Jun; 27(6):513-522. PubMed ID: 29855199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8.
    Mandato E; Yan Q; Ouyang J; Paczkowska J; Qin Y; Hao Y; Bojarczuk K; Hansen J; Chapuy B; Rodig SJ; Khan SJ; Redd RA; Shipp MA
    Blood; 2023 Oct; 142(14):1219-1232. PubMed ID: 37467575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects.
    Eiken AP; Smith AL; Skupa SA; Schmitz E; Rana S; Singh S; Kumar S; Mallareddy JR; de Cubas AA; Krishna A; Kalluchi A; Rowley MJ; D'Angelo CR; Lunning MA; Bociek RG; Vose JM; Natarajan A; El-Gamal D
    Cancer Res Commun; 2024 May; 4(5):1328-1343. PubMed ID: 38687198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell receptor signaling in diffuse large B-cell lymphoma.
    Young RM; Shaffer AL; Phelan JD; Staudt LM
    Semin Hematol; 2015 Apr; 52(2):77-85. PubMed ID: 25805587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
    Ondrisova L; Mraz M
    Front Oncol; 2020 Oct; 10():591577. PubMed ID: 33154951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma.
    Krysiak K; Gomez F; White BS; Matlock M; Miller CA; Trani L; Fronick CC; Fulton RS; Kreisel F; Cashen AF; Carson KR; Berrien-Elliott MM; Bartlett NL; Griffith M; Griffith OL; Fehniger TA
    Blood; 2017 Jan; 129(4):473-483. PubMed ID: 28064239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunoglobulin tail tyrosine motif upgrades memory-type BCRs by incorporating a Grb2-Btk signalling module.
    Engels N; König LM; Schulze W; Radtke D; Vanshylla K; Lutz J; Winkler TH; Nitschke L; Wienands J
    Nat Commun; 2014 Nov; 5():5456. PubMed ID: 25413232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy.
    Packham G; Krysov S; Allen A; Savelyeva N; Steele AJ; Forconi F; Stevenson FK
    Haematologica; 2014 Jul; 99(7):1138-48. PubMed ID: 24986876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL.
    Eken JA; Koning MT; Kupcova K; Sepúlveda Yáñez JH; de Groen RAL; Quinten E; Janssen J; van Bergen CAM; Vermaat JSP; Cleven A; Navarrete MA; Ylstra B; de Jong D; Havranek O; Jumaa H; Veelken H
    J Exp Med; 2024 May; 221(5):. PubMed ID: 38512136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas.
    Choi J; Ceribelli M; Phelan JD; Häupl B; Huang DW; Wright GW; Hsiao T; Morris V; Ciccarese F; Wang B; Corcoran S; Scheich S; Yu X; Xu W; Yang Y; Zhao H; Zhou J; Zhang G; Muppidi J; Inghirami GG; Oellerich T; Wilson WH; Thomas CJ; Staudt LM
    Cancer Cell; 2024 May; 42(5):833-849.e12. PubMed ID: 38701792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.
    Frezzato F; Gattazzo C; Martini V; Trimarco V; Teramo A; Carraro S; Cabrelle A; Ave E; Facco M; Zambello R; Tibaldi E; Brunati AM; Semenzato G; Trentin L
    PLoS One; 2012; 7(6):e39902. PubMed ID: 22768161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.
    Munshi M; Liu X; Chen JG; Xu L; Tsakmaklis N; Demos MG; Kofides A; Guerrera ML; Jimenez C; Chan GG; Hunter ZR; Palomba ML; Argyropoulos KV; Meid K; Keezer A; Gustine J; Dubeau T; Castillo JJ; Patterson CJ; Wang J; Buhrlage SJ; Gray NS; Treon SP; Yang G
    Blood Cancer J; 2020 Jan; 10(1):12. PubMed ID: 32005797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas.
    Shah SB; Carlson CR; Lai K; Zhong Z; Marsico G; Lee KM; Félix Vélez NE; Abeles EB; Allam M; Hu T; Walter LD; Martin KE; Gandhi K; Butler SD; Puri R; McCleary-Wheeler AL; Tam W; Elemento O; Takata K; Steidl C; Scott DW; Fontan L; Ueno H; Cosgrove BD; Inghirami G; García AJ; Coskun AF; Koff JL; Melnick A; Singh A
    Nat Mater; 2023 Apr; 22(4):511-523. PubMed ID: 36928381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.